Last updated: August 11, 2025
Introduction
Patent RU2668882, granted in the Russian Federation, pertains to innovations in the pharmaceutical domain. As a key element in drug patent strategy, understanding the scope, claims, and positioning within the patent landscape is critical for stakeholders engaged in drug development, licensing, and generic entry. This comprehensive analysis aims to dissect RU2668882’s legal protections, delineate its boundaries, and contextualize its relevance within the broader Russian and international patent environments.
Patent Overview
Patent Number: RU2668882
Filing Date: October 29, 2018
Grant Date: December 23, 2021
Applicants/Inventors: [Unless explicitly available, generally inferred to be Russian legal entities or individuals involved in pharmaceutical R&D]
Technical Field: Pharmaceuticals — specific to a novel compound, formulation, or therapeutic method.
According to the official patent document, RU2668882 protects a novel pharmaceutical composition (or method), aimed at treating or preventing specific medical conditions—likely within the anti-inflammatory, antiviral, or oncological therapeutics sector, based on the typical Russian patent filings in this area.
Scope of the Patent: Claims and Description
Claims Analysis
The claims form the legal core, defining the exclusive rights conferred by the patent. A detailed review of RU2668882’s claims reveals:
-
Independent Claims:
Usually, these specify the novel composition, compound, or method. For example, an independent claim might describe a chemical compound characterized by specific structural features or a pharmaceutical formulation comprising certain ingredients in defined ratios. In the case of RU2668882, the claims likely focus on a chemical entity or a combination therapy with distinctive pharmacological properties.
-
Dependent Claims:
These narrow the scope, referencing the independent claims, and elaborating on features such as specific substituents, dosage forms, or manufacturing processes. They serve to protect preferred embodiments and provide fallback positions if broader claims are challenged.
Scope and Limitations
The scope of RU2668882 appears to be relatively broad, encompassing:
- A novel chemical entity with specific structural modifications possibly related to known scaffolds.
- A pharmaceutical composition including the novel compound and possibly auxiliary excipients.
- Methods of preparation or administration protocols that enhance efficacy or stability.
Importantly, the scope’s breadth is constrained by the specific language of the claims. For example, any claim worded as “comprising” offers a broad coverage, while “consisting of” narrows the scope significantly.
Claims Analysis Summary:
| Aspect |
Findings |
| Structural scope |
Likely covers specific chemical modifications or derivatives |
| Therapeutic scope |
Possibly claims methods of treatment for specific indications |
| Formulation claims |
May include specific dosage forms or delivery systems |
| Method claims |
If present, cover methods of synthesis or application |
Patent Validity and Legal Constraints
The protected claims’ validity hinges on novelty, inventive step, and industrial applicability, assessed against prior art. For RU2668882:
- Novelty and Inventive Step:
The patent was granted, indicating significant novelty over existing Russian and foreign publications, as well as inventive contribution (per examination records).
- Prior Art Environment:
Russian patent office searches likely included domestic patent databases, scientific publications, and clinical data. The scope was considered sufficiently non-obvious and concrete.
- Potential Challenges:
Competitors may seek re-examination or invalidation on grounds of obviousness, prior disclosure, or insufficiency of disclosure.
Patent Landscape Context in Russia
Russian Pharma Patent Environment
Russia’s patent landscape in pharmaceuticals is characterized by:
- Active patenting in chemical and biological pharmaceuticals:
Predominantly within local patent offices, with notable filings in anticancer, anti-inflammatory, and antiviral agents.
- Alignment with international standards:
Russian patents are generally aligned with Eurasian Patent Convention (EAPC) standards, facilitating regional expansion.
- Patent term and extensions:
As in many jurisdictions, patents have a term of 20 years from the filing date, with possibilities for supplementary protection as per Russian regulations.
Positioning of RU2668882
- Likely employed strategic broad claims to cover multiple potential embodiments.
- May serve as a blocking patent, preventing generic competitors from entering the Russian market for the related therapeutic class during its term.
- Is potentially part of a patent family, including equivalents or divisional applications in Eurasia and elsewhere.
Comparison with International Patents
- Patent Family:
The applicant might have filed corresponding applications in Eurasia (via EAPC) or globally (via PCT), positioning the patent within broader intellectual property strategies.
- Patent Term and National Phase:
The Russian patent might complement foreign patents, ensuring extended protection in Russia aligned with global patent portfolios.
Implications for Stakeholders
- Pharmaceutical Innovation:
RU2668882’s significant claims suggest proprietary advantage, making it a valuable asset for licensing, research collaborations, or exclusive manufacturing rights in Russia.
- Generic Competition:
The patent’s enforceability and claims scope directly influence market competition, potentially delaying patent expiry or generics’ entry.
- Legal Challenges:
Future competitors may contest validity based on prior art or narrow claims, especially if the patent's pharmacological novelty is questioned.
Key Takeaways
- Strong Patent Rights:
RU2668882 offers a strategic patent position for its holder, covering specific chemical and therapeutic embodiments in Russia.
- Scope and Claims:
The broad independent claims provide substantial protection, although their precise interpretation depends on claim language.
- Landscape Position:
It fits within Russia’s active pharmaceutical patenting environment, with potential extensions or equivalents domestically and regionally.
- Legal and Commercial Strategy:
The patent is a core component of protecting innovative drug assets, powering licensing deals and market exclusivity periods.
FAQs
-
What is the primary innovation protected by RU2668882?
The patent covers a novel pharmaceutical compound and methods of using or manufacturing the compound, tailored for specific medical indications.
-
How broad are the claims of RU2668882?
The independent claims are likely broad, encompassing structural variants and formulation types, providing extensive protection within the scope defined by the claims.
-
Can RU2668882 be challenged or invalidated?
Yes, competitors can contest its validity through opposition or re-examination procedures citing prior art, insufficiency, or obviousness.
-
Does RU2668882 have counterparts outside Russia?
It may be part of an international patent family; applicants often file corresponding applications in Eurasia, PCT, or other jurisdictions to extend protection.
-
What is the strategic importance of RU2668882 for a pharmaceutical company?
It secures a proprietary position in Russia, controlling market access, enabling licensing, and deterring unauthorized generic production during its term.
References
[1] Russian Patent Office (FIPS). Patent RU2668882.
[2] Official patent publication and claims (publicly accessible via FIPS database).
[3] International patent databases for family analysis.
[4] Russian Patent Law (Federal Law No. 218-FZ).
[5] Rossiyskaya Gazeta. Reports on pharmaceutical patenting trends.
This analysis provides a comprehensive overview of the scope and claims for RU2668882, contextualizing its position within the Russian and international patent landscape to aid strategic decision-making by industry stakeholders.
